CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood cytokine storm-driven inflammatory disorder. Interleukin-6 (IL-6) is a known disease driver in some patients, but anti-IL-6 therapy with siltuximab is not effective in all patients, and biomarkers indicating success at...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierson, Sheila K., Katz, Laura, Williams, Reece, Mumau, Melanie, Gonzalez, Michael, Guzman, Stacy, Rubenstein, Ayelet, Oromendia, Ana B., Beineke, Philip, Fosså, Alexander, van Rhee, Frits, Fajgenbaum, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700691/
https://www.ncbi.nlm.nih.gov/pubmed/36433996
http://dx.doi.org/10.1038/s41467-022-34873-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700691/
https://www.ncbi.nlm.nih.gov/pubmed/36433996
http://dx.doi.org/10.1038/s41467-022-34873-7

Ejemplares similares